Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: A retrospective study of 36 patients at mayo clinic

Timothy J. Poterucha, Sinead L. Murphy, Mark D P Davis, Paola Sandroni, Richard H. Rho, Roger A. Warndahl, William T. Weiss

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Erythromelalgia is an uncommon neurovascular disorder characterized by redness, increased skin temperature, and pain that usually occurs in the extremities. Treatment remains challenging because of its varying response to medical therapy. The objective of this study was to assess the response of erythromelalgia to compounded topical amitriptyline-ketamine. Methods: We retrospectively evaluated 36 patients with erythromelalgia who were treated with compounded topical amitriptyline-ketamine from January 1, 2004, through January 31, 2011. Results: Thirty-two patients (89%) were female. Mean (standard deviation) age was 44.7 (15.8) years (range, 5-74 years). Patients applied the medication 1 to 6 times per day (median, 5 times). One patient (3%) had complete relief from symptoms, 14 (39%) had substantial relief, 12 (33%) had some relief, 7 (19%) had no relief, and 2 (6%) had local worsening of symptoms. No patients had systemic adverse effects. Conclusions: A majority of patients with erythromelalgia (75%) reported improvement in pain with topical application of a compounded amitriptyline-ketamine formulation. The medication was well tolerated.

Original languageEnglish (US)
Pages (from-to)308-310
Number of pages3
JournalJournal of Drugs in Dermatology
Volume12
Issue number3
StatePublished - Mar 2013

Fingerprint

Erythromelalgia
Amitriptyline
Ketamine
Retrospective Studies
Therapeutics
Pain
Skin Temperature
Extremities

ASJC Scopus subject areas

  • Dermatology

Cite this

Poterucha, T. J., Murphy, S. L., Davis, M. D. P., Sandroni, P., Rho, R. H., Warndahl, R. A., & Weiss, W. T. (2013). Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: A retrospective study of 36 patients at mayo clinic. Journal of Drugs in Dermatology, 12(3), 308-310.

Topical amitriptyline combined with ketamine for the treatment of erythromelalgia : A retrospective study of 36 patients at mayo clinic. / Poterucha, Timothy J.; Murphy, Sinead L.; Davis, Mark D P; Sandroni, Paola; Rho, Richard H.; Warndahl, Roger A.; Weiss, William T.

In: Journal of Drugs in Dermatology, Vol. 12, No. 3, 03.2013, p. 308-310.

Research output: Contribution to journalArticle

Poterucha, TJ, Murphy, SL, Davis, MDP, Sandroni, P, Rho, RH, Warndahl, RA & Weiss, WT 2013, 'Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: A retrospective study of 36 patients at mayo clinic', Journal of Drugs in Dermatology, vol. 12, no. 3, pp. 308-310.
Poterucha, Timothy J. ; Murphy, Sinead L. ; Davis, Mark D P ; Sandroni, Paola ; Rho, Richard H. ; Warndahl, Roger A. ; Weiss, William T. / Topical amitriptyline combined with ketamine for the treatment of erythromelalgia : A retrospective study of 36 patients at mayo clinic. In: Journal of Drugs in Dermatology. 2013 ; Vol. 12, No. 3. pp. 308-310.
@article{66cde9f2aa3c47aebe0a5163814d29ae,
title = "Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: A retrospective study of 36 patients at mayo clinic",
abstract = "Background: Erythromelalgia is an uncommon neurovascular disorder characterized by redness, increased skin temperature, and pain that usually occurs in the extremities. Treatment remains challenging because of its varying response to medical therapy. The objective of this study was to assess the response of erythromelalgia to compounded topical amitriptyline-ketamine. Methods: We retrospectively evaluated 36 patients with erythromelalgia who were treated with compounded topical amitriptyline-ketamine from January 1, 2004, through January 31, 2011. Results: Thirty-two patients (89{\%}) were female. Mean (standard deviation) age was 44.7 (15.8) years (range, 5-74 years). Patients applied the medication 1 to 6 times per day (median, 5 times). One patient (3{\%}) had complete relief from symptoms, 14 (39{\%}) had substantial relief, 12 (33{\%}) had some relief, 7 (19{\%}) had no relief, and 2 (6{\%}) had local worsening of symptoms. No patients had systemic adverse effects. Conclusions: A majority of patients with erythromelalgia (75{\%}) reported improvement in pain with topical application of a compounded amitriptyline-ketamine formulation. The medication was well tolerated.",
author = "Poterucha, {Timothy J.} and Murphy, {Sinead L.} and Davis, {Mark D P} and Paola Sandroni and Rho, {Richard H.} and Warndahl, {Roger A.} and Weiss, {William T.}",
year = "2013",
month = "3",
language = "English (US)",
volume = "12",
pages = "308--310",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

TY - JOUR

T1 - Topical amitriptyline combined with ketamine for the treatment of erythromelalgia

T2 - A retrospective study of 36 patients at mayo clinic

AU - Poterucha, Timothy J.

AU - Murphy, Sinead L.

AU - Davis, Mark D P

AU - Sandroni, Paola

AU - Rho, Richard H.

AU - Warndahl, Roger A.

AU - Weiss, William T.

PY - 2013/3

Y1 - 2013/3

N2 - Background: Erythromelalgia is an uncommon neurovascular disorder characterized by redness, increased skin temperature, and pain that usually occurs in the extremities. Treatment remains challenging because of its varying response to medical therapy. The objective of this study was to assess the response of erythromelalgia to compounded topical amitriptyline-ketamine. Methods: We retrospectively evaluated 36 patients with erythromelalgia who were treated with compounded topical amitriptyline-ketamine from January 1, 2004, through January 31, 2011. Results: Thirty-two patients (89%) were female. Mean (standard deviation) age was 44.7 (15.8) years (range, 5-74 years). Patients applied the medication 1 to 6 times per day (median, 5 times). One patient (3%) had complete relief from symptoms, 14 (39%) had substantial relief, 12 (33%) had some relief, 7 (19%) had no relief, and 2 (6%) had local worsening of symptoms. No patients had systemic adverse effects. Conclusions: A majority of patients with erythromelalgia (75%) reported improvement in pain with topical application of a compounded amitriptyline-ketamine formulation. The medication was well tolerated.

AB - Background: Erythromelalgia is an uncommon neurovascular disorder characterized by redness, increased skin temperature, and pain that usually occurs in the extremities. Treatment remains challenging because of its varying response to medical therapy. The objective of this study was to assess the response of erythromelalgia to compounded topical amitriptyline-ketamine. Methods: We retrospectively evaluated 36 patients with erythromelalgia who were treated with compounded topical amitriptyline-ketamine from January 1, 2004, through January 31, 2011. Results: Thirty-two patients (89%) were female. Mean (standard deviation) age was 44.7 (15.8) years (range, 5-74 years). Patients applied the medication 1 to 6 times per day (median, 5 times). One patient (3%) had complete relief from symptoms, 14 (39%) had substantial relief, 12 (33%) had some relief, 7 (19%) had no relief, and 2 (6%) had local worsening of symptoms. No patients had systemic adverse effects. Conclusions: A majority of patients with erythromelalgia (75%) reported improvement in pain with topical application of a compounded amitriptyline-ketamine formulation. The medication was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=84874644617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874644617&partnerID=8YFLogxK

M3 - Article

C2 - 23545913

AN - SCOPUS:84874644617

VL - 12

SP - 308

EP - 310

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -